Evidence map›Paper›PMID 29891227›Full record

ReviewTrends in cell biology2018

Analyzing Circulating Tumor Cells One at a Time.

Veronica Ortiz, Min Yu

Abstract readReview
In one paragraph

Review in Trends in cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Circulating tumour cell isolation, analysis and clinical application.Cellular oncology (Dordrecht, Netherlands) · 2023
    Review
  6. Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Circulating tumor cells in colorectal cancer in the era of precision medicine.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  11. Review
  12. Article
  13. Long non-coding RNAs: the tentacles of chromatin remodeler complexes.Cellular and molecular life sciences : CMLS · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Veronica OrtizDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Min YuDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: minyu@med.usc.edu.

Funding

Developing Individualized Medicine Targeting Metastatic Breast Cancer Stem CellsDP2CA206653 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YU, MIN · 2015 to 2019
$2.6M
Characterizing the role of TAK1 in breast cancer metastasisK22CA175228 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YU, MIN · 2014 to 2016
$592k
Heterogeneity of DNA methylomes between circulating tumor cellsF31CA213970 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ORTIZ, VERONICA · 2016 to 2020
$159k
NCI NIH HHS DP2 CA206653NCI NIH HHS F31 CA213970NCI NIH HHS K22 CA175228
6 · The paper itself

Abstract

Whole-genome sequencing has made a significant impact on cancer research, but traditional bulk methods fail to detect information from rare cells. Recently developed single-cell sequencing methods have provided new insights and unprecedented details about cancer progression and diversity. These advancements also enable the investigation of rare cells, such as circulating tumor cells (CTCs) derived from cancer patients. In this review, we outline various single-cell sequencing techniques that can elucidate the molecular properties of CTCs. In addition, we explain the drawbacks that need to be overcome for each method.

Indexed as

Single-Cell AnalysisHumansNeoplasmsNeoplastic Cells, CirculatingCirculating tumor cellssingle-cell sequencingtumor heterogeneity

Identifiers

PMID29891227
PMCPMC6153072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.